My laboratory is interested in understanding how epigenetic modifiers regulate normal and malignant T lymphocytes. Specifically, we are focusing on DNA methylation enzymes – the methylcytosine dioxygenase TET2 and the DNA methyltransferase DNMT3A – in directing normal T cell fate decisions in CD4+ and CD8+ T cells during immune responses. In addition, since both of these enzymes are frequently mutated in a subset of human peripheral T cell lymphomas (PTCLs), we are interested in how epigenetic dysregulation can contribute to T cell transformation and cooperate with co-occurring PTCL mutations in the pathogenesis of T cell lymphomas.